We would like to thank you for the opportunity to respond to the questions posed by Dr Bamat as well as thank him and his team for their interest in our article.
1. Of the 30 patients in our cost analysis study, data was available for 25 patients who had 5FU toxicity; 9 patients were "early onset," that is, toxicity occurred after 1 cycle of 5FU and 16 patients were "cumulative onset," that is, toxicity occurred following 2 or more cycles of 5FU. 2. In patients who did not have a discernible DPYD mutation (n ¼ 4. Toxicity types: DPYD mutant v wild-type a. In the 5 patients who were DPYD mutant; i. 2 patients had GI and hematologic toxicity (40%) ii. 3 patients had GI toxicity alone (60%) b. In the 20 patients who were DPYD wild-type;
i. 12 patients had GI toxicity alone (60%) ii. 4 patients had hematologic toxicity alone (20%) iii. 2 patients had GI and hematologic toxicity (10%) iv. 1 patient had GI toxicity and Hand Foot syndrome (5%) v. 1 patient had cardiotoxicity (5%) 5. As per above one patient in this data set had cardiotoxicity-early onset coronary vasospasm.
I hope this information is of benefit to you in your future 5FU toxicity research.
